Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week onc...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Mateos, María-Victoria, Bringhen, Sara, Richardson, Paul G., Lahuerta, Juan Jose, Larocca, Alessandra, Oriol, Albert, Boccadoro, Mario, García-Sanz, Ramón, Di Raimondo, Francesco, Esseltine, Dixie-Lee, van de Velde, Helgi, Desai, Avinash, Londhe, Anil, San Miguel, Jesús F., Palumbo, Antonio
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2014
Предметы:
Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4040917/
https://ncbi.nlm.nih.gov/pubmed/24763402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.099341
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы